Formylcolchicine bound to lactosaminated serum albumin is a more active antifibrotic agent than free colchicine

The effects of colchicine treatment on wound healing in a caustic murine injury model

OBJECTIVE

The present study determined the effects of colchicine on wound repair in a murine model of dermal chemical injury.

METHODS

Standardized 4.15 cm2 circular lesions were induced on the dorsum of adult male mice with NaOH. Five minutes of IN or 3N caused lesions of graded depth. Mice received colchicine (1 mg/kg) or phosphate-buffered saline intraperitoneally in equivalent volumes. Treatment began immediately postinjury and was continued on an alternating day schedule for 14 days. Wound size was measured every third day postinjury. On day 15 postinjury, wounds were histologically graded for depth of injury, degree of fibrosis, inflammatory cell response, and revascularization. All histological determinations and wound measurements were performed in a blinded fashion.

RESULTS

All mice had a similar initial wound size and completed the experimental protocol. In dermal wounds of superficial depth, colchicine-treated mice (n = 20) had a larger wound size during days 6 through 9 of the experimental trial when compared to phosphate-buffered saline-treated mice (n = 18). In the deeper wounds, there were no significant differences in wound size between colchicine and phosphate-buffered saline-treated groups. Colchicine (n = 54) did not affect the degree of fibrosis at all depths of injury vs phosphate-buffered saline treatment in mice (n = 55). The degree of wound revascularization was less in colchicine-treated mice (n = 54) than phosphate-buffered saline-treated mice (n = 55).

CONCLUSION

Colchicine did not improve wound healing in an alkaline-induced dermal injury.

Colchicine: 1998 update

OBJECTIVE

To present an update of the use of colchicine in patients with familial Mediterranean fever (FMF) and other rheumatic and nonrheumatic diseases.

DATA SOURCES

Published studies on colchicine retrieved from MEDLINE searches from 1987 to 1997 and reports presented at national and international meetings. STUDIES SELECTION AND EXTRACTION: All studies were reviewed by the authors. Reports addressing the topics of colchicine pharmacokinetics, biological effects, indications for use, and side effects were selected.

DATA SYNTHESIS

Colchicine is an alkaloid that may interfere with microtubule formation, thereby affecting mitosis and other microtubule-dependent functions. It has a bioavailability of 25% to 50% when administered orally. Colchicine and its metabolites are excreted through the urinary and biliary tracts. It may be used while breast feeding; however, amniocentesis should be performed when used in pregnancy. The drug may be given to children with FMF. The efficacy of colchicine has been proved in FMF, gout, Behcet's disease, and cirrhosis. Its place in the treatment of scleroderma, sarcoidosis, and skin disorders remains to be determined. Gastrointestinal side effects occur early and are most common manifestations of colchicine toxicity. Severe colchicine toxicity results in multiple organ failure, convulsions, coma, and death. Potentially, effective treatment with Fab anti-colchicine antibodies unfortunately is unavailable; therefore, treatment is supportive.

CONCLUSIONS

Colchicine is a relatively safe and effective medication for several disorders when used in appropriate dosage in patients with normal kidney and liver function.